Abstract：Objective To measure the expression of lymphocyte function-associated antigen-3 (CD58) in childhood B-lineage acute lymphoblastic leukemia (B-ALL) and to explore the feasibility of CD58 as an indicator for minimal residual disease (MRD) detection in childhood B-ALL. Methods Eighty-seven children diagnosed with B-ALL between January 2014 and September 2014 were enrolled, and 20 hospitalized children who had no tumor or blood disease and had normal bone marrow cell morphology served as the control group. The expression features of CD58 in bone marrow samples from the two groups (at diagnosis, on day 15 of induction chemotherapy) were analyzed by four-color flow cytometry (FCM). Quantitative real-time polymerase chain reaction (qRT-PCR) and FCM were used to detect MRD in B-ALL patients on day 33 of induction chemotherapy. Results The mean fluorescence intensity of CD58 expression in the 87 B-ALL cases (91±33) was significantly higher than that in the 20 controls (14±6) (P< 0.01); CD58 was over-expressed in 44 of the B-ALL cases. In the B-ALL children, the expression of CD58 on day 15 of induction chemotherapy (105±22) was not significantly different from that at diagnosis (107±26) (P> 0.05). In the 44 B-ALL patients with CD58 over-expression, FCM showed 9 MRD(+) cases and 35 MRD(-) cases, while qRT-PCR showed 11 MRD(+) cases and 33 MRD(-) cases; 42 cases (95%) showed consistent results of the two tests, so there was no significant difference between the two methods in detecting MRD (P> 0.05). Conclusions CD58 is over-expressed and stable in children with B-ALL, and it can be considered as an indicator for MRD detection in childhood B-ALL.
LI Ya-Fei,ZHAO Xiao-Ming,SHENG Guang-Yao et al. Expression of CD58 in childhood B-lineage acute lymphoblastic leukemia and its feasibility in minimal residual disease detection[J]. CJCP, 2015, 17(8): 825-829.
Patkar N, Alex AA, Ahmed R, et al. Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country[J]. Cytometry B Clin Cytom, 2012, 82(4): 252-258.
[3]
Liu Q, Wang M, Hu Y, et al. Significance of CD71 expression by flow cytometry in diagnosis of acute leukemia[J]. Leuk Lymphoma, 2014, 55(4): 892-898.
[4]
Lee RV, Braylan RC, Rimsza LM. CD58 expression decreases as nonmalignant B cells mature inbone marrow and is frequently overexpressed in adult and pediatric precursor B cell acute lymphoblastic leukemia[J]. Am J Clin Pathol, 2005, 123(1): 119-124.
Garand R, Beldjord K, Cave H, et al. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL[J]. Leukemia, 2013, 27(2): 370-376.
Gaipa G, Basso G, Biondi A, et al. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia[J]. Cytometry B Clin Cytom, 2013, 84(6):359-369.
[9]
Lutz C, Woll PS, Hall G, et al. Quiescent leukemic cells account for minimal residual disease in children lymphoblastic leukemia[J]. Leukemia, 2013, 27(5): 1204-1207.
[10]
Zhao XS, Liu YR, Zhu HH, et al. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation[J]. Ann Hematol, 2012, 91(2): 183-192.
Comerci CJ, Mace EM, Banerjee PP. CD2 promotes human natural killer cell membrane nanotube formation[J]. PLoS One, 2012, 7(10): e47664.
[13]
Nina F, Lars P, Ryder, et al. Identification of residual leukemic cells by flow cytometry in childhood B-cell precursor acute lymphoblastic leukemia: verification of leukemic state by flow-sorting and molecular/cytogenetic methords[J]. Haematologica, 2012, 97(1): 137-141.
[14]
Thörn I, Forestier E, Botling J, et al. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry[J]. Br J Haematol, 2011, 152(6): 743-753.
[15]
Denys B, van der Sluijs-Gelling AJ, Homburg C, et al. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia[J]. Leukemia, 2013, 27(3): 635-641.
[16]
Ratei R, Basso G, Dworzak M, et al. Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction[J]. Leukemia, 2009, 23(3): 528-534.
Sędek Ł, Bulsa J, Sonsala A, et al. The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts?[J]. Cytometry B Clin Cytom, 2014, 86(5): 329-339.
